MedTrace Logo

A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

NCT06677307 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-04-17

No results posted yet for this study

Summary

The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).

Conditions

  • Alpha-1 Anti-trypsin Deficiency
  • AATD

Interventions

DRUG

KRRO-110

KRRO-110 drug product, IV

Sponsors & Collaborators

  • Korro Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Korro Bio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-13
Primary Completion
2025-10-31
Completion
2025-12-15

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06677307 on ClinicalTrials.gov